STAMFORD, Conn., July 21 /PRNewswire-FirstCall/ -- Zargis Medical
Corp., a majority-owned subsidiary of Speedus Corp. (Nasdaq: SPDE),
today announced that it received a contract from the U.S. Army to
develop an investigational device based on the success of the
Signal-X6™ telemedicine systems recently deployed to the Army under
a separate contract. Under the terms of the new contract, Zargis
will develop prototype versions of the Signal-X6 system that will
incorporate automated heart sound detection and murmur
classification functionality similar to that offered by the
award-winning Zargis Cardioscan software. This $120,000 contract will commence on August 1st, 2010.
Due to the fact that each Signal-X6 device incorporates six
acoustic sensors that simultaneously record sounds from a patient's
torso, this new project will allow Zargis to enhance its
proprietary heart sounds analysis technology by leveraging
multi-channel heart sound input instead of relying on input from
the single sensor contained in a stethoscope.
"We are excited about this latest chapter in our ongoing
relationship with the U.S. Army," stated Zargis CEO John Kallassy. "As our Signal-X6 systems
continue to be evaluated throughout the Army's Military Treatment
Facilities, we anticipate that the integration of our heart sounds
analysis algorithms will lead the Army, and others, to deploy our
devices on a wider scale."
Zargis expects that clinical data obtained regarding this
project will culminate in the development of an Army-sponsored
research paper.
The development of the investigational device described in the
contract is being funded by the Telemedicine and Advanced
Technology Research Center (TATRC) through the AAMTI program. The
AAMTI program provides funding to AMEDD personnel to demonstrate
technology and document the impact on cost, access and quality of
care. TATRC (www.tatrc.org) is an element of the United States Army
Medical Research and Materiel Command (USAMRMC).
About Zargis Medical Corp.
Zargis is a global medical device company focused on improving
health outcomes and cost-effectiveness through diagnostic support
software and innovation. Zargis is majority-owned by Speedus Corp.
(Nasdaq: SPDE), and both 3M Company and Siemens Corporate Research,
a division of Siemens AG (NYSE: SI), hold equity positions.
For additional information about Zargis or Speedus Corp.,
contact Peter Hodge at 888.773.3669
(ext. 23) or phodge@zargis.com, or visit the following Web sites:
www.zargis.com and www.speedus.com.
Statements contained herein that are not historical facts,
including but not limited to statements about the Company's
product, corporate identity and focus, may be forward-looking
statements that are subject to a variety of risks and
uncertainties. There are a number of important factors that could
cause actual results to differ materially from those expressed in
any forward-looking statements made by the Company, including, but
not limited to, the continuing development of the Company's sales,
marketing and support efforts.
SOURCE Speedus Corp.
